Tanabe Pharma Corporation
Clinical trials sponsored by Tanabe Pharma Corporation, explained in plain language.
-
New hope for aggressive lymphoma: drug MT-2111 under trial
Disease control OngoingThis study tests a drug called MT-2111 (loncastuximab tesirine) in people with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to at least two prior treatments. The trial has two parts: first, to find a safe dose, and second…
Phase: PHASE1, PHASE2 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug aims to soften skin in rare autoimmune disease
Disease control OngoingThis study tests an experimental drug called MT-0551 against a placebo in 80 adults with systemic sclerosis, a disease that causes skin thickening and can affect internal organs. The main goal is to see if the drug reduces skin hardness over 26 weeks. Researchers will also check …
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC